BPC-157 15mg/mL

Route: Subcutaneous or intramuscular injection as prescribed.

• Inject subcutaneously (or intramuscularly as directed) into designated sites; rotate injection sites to prevent local tissue reactions.
• Use strict aseptic technique: disinfect the injection site with alcohol, allow to dry, then administer the prescribed volume.
• Inspect the solution before each use; do not administer if the solution is cloudy, discolored, or contains visible particles.
• Use a new sterile syringe and needle for each injection.

Dosing is entirely prescriber-determined. The 15 mg/mL concentration provides dosing flexibility for patients requiring higher per-dose quantities or more concentrated volumes:

• No FDA-established dosing protocol exists for BPC-157 in humans.
• The prescriber specifies dose in mg or mL, frequency, route, and duration based on the patient's clinical circumstances and available evidence.
• The higher concentration (15 mg/mL vs. 10 mg/mL) allows delivering the same milligram dose in a smaller injection volume if needed.

The mechanism of action of BPC-157 is the same regardless of concentration. Based on preclinical research:

• BPC-157: Activates FAK-paxillin signaling to enhance cell migration and tissue repair; stimulates VEGF-mediated neoangiogenesis; modulates nitric oxide synthesis to improve local microvascular perfusion; inhibits prostaglandin synthesis and reduces neutrophilic infiltration (anti-inflammatory); demonstrates mucosal cytoprotection in the gastrointestinal tract and accelerates healing of tendons, ligaments, muscle, and bone in animal models.

Clinical context and monitoring considerations are identical to the 10 mg/mL preparation. The 15 mg/mL concentration is a prescriber-selected alternative based on dosing convenience or specific dose requirements. All caveats regarding investigational status, absence of FDA-approved indications, and limited human clinical trial data apply equally to this formulation.

Prescriber monitoring:

• Monitor injection sites at each visit for erythema, pain, or signs of infection.
• Reassess the treatment rationale, patient response, and any adverse effects at regular intervals.
• Document informed consent and awareness of investigational status.

Contraindications:

• Known hypersensitivity to BPC-157 or formulation components
• Active malignancy (angiogenic properties; avoid until further clinical data are available)

Warnings & Precautions:

• Not FDA-approved; long-term human safety data are not available.
• Higher concentration does not change the safety profile qualitatively, but dosing errors at 15 mg/mL deliver 50% more drug per mL than the 10 mg/mL formulation; careful verification of prescribed volume is critical.
• Sterile injectable preparations require aseptic technique to prevent infection.
• Prescribers must ensure patients have been fully informed of the investigational nature of this therapy.

Drug Interactions:

• No established human drug interactions; limited clinical pharmacokinetic data available.

Common Side Effects: Injection site reactions (erythema, bruising, pain); systemic safety profile in humans remains under investigation based on available pilot-scale data.

Store refrigerated at 2–8°C (36–46°F). Protect from light. Do not freeze. Bring to room temperature prior to injection. Discard unused portions and do not use after the beyond-use date assigned by Genesis Compounding per USP sterile compounding standards.

What is the difference between 10 mg/mL and 15 mg/mL BPC-157?

The only difference is concentration. The 15 mg/mL preparation delivers 15 mg of BPC-157 per mL of solution, compared to 10 mg per mL in the lower-concentration formulation. This allows the same milligram dose to be injected in a smaller volume, which may improve injection comfort or better suit a specific dosing protocol.

Is this formulation more potent or more effective than the 10 mg/mL?

The pharmacological activity of BPC-157 depends on the milligram dose administered, not the concentration. The 15 mg/mL formulation is not inherently more potent; it simply allows greater dosing flexibility in a smaller injection volume.

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any indication. This is a 503A compounded sterile preparation from Genesis Compounding, prepared for a specific patient per a prescriber's order. Patients must be informed of its investigational status.

How should I handle and store this injection?

Refrigerate at 2–8°C. Protect from light. Do not freeze. Inspect for clarity before each use. Use new sterile supplies for each injection. Use before the labeled beyond-use date.

What should I tell my prescriber if I experience side effects?

Contact your prescriber promptly if you experience severe injection site reactions, systemic symptoms such as fever or chills, or any unexpected effects. Because human safety data are limited, all adverse events should be reported to the prescriber for documentation and clinical management.